SC
Steve Chesney Redburn Atlantic Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $545 |
38%
upside
| Buy |
27 Jun ‘24
1 year ago |
|
2
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $54 |
15%
upside
| Neutral |
6 Feb ‘24
1 year ago |
|
3
Biogen
BIIB
$20.6B
| $140.67 | $275 |
95%
upside
| Neutral |
8 Aug ‘23
2 years ago |
|
4
Johnson & Johnson
JNJ
$430B
| $178.43 | $170 |
5%
downside
| Neutral |
4 Aug ‘23
2 years ago |
|
5
Idexx Laboratories
IDXX
$51.4B
| $642.99 | $600 |
7%
downside
| Neutral |
2 Aug ‘23
2 years ago |
|
|
6
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $85 |
80%
upside
| Overweight |
28 Jul ‘23
2 years ago |
|
7
Zoetis
ZTS
$67.9B
| $153.32 | $225 |
47%
upside
| Overweight |
14 Jun ‘23
2 years ago |
|
8
Merck
MRK
$212B
| $84.71 | $129 |
52%
upside
| Overweight |
1 May ‘23
2 years ago |
|
9
AbbVie
ABBV
$375B
| $212.56 | $154 |
28%
downside
| Neutral |
10 Feb ‘23
2 years ago |
|
10
Pfizer
PFE
$141B
| $24.88 | $46 |
85%
upside
| Neutral |
1 Feb ‘23
2 years ago |
|
11
Amgen
AMGN
$153B
| $283.64 | $182 |
36%
downside
| Underweight |
9 Aug ‘22
3 years ago |
|